Jimerson D C, Wolfe B E, Brotman A W, Metzger E D
Department of Psychiatry, Beth Israel Hospital, Boston, Massachusetts, USA.
Psychiatr Clin North Am. 1996 Dec;19(4):739-54. doi: 10.1016/s0193-953x(05)70378-6.
Effective planning for medication treatment in patients with bulimia nervosa and anorexia nervosa is based on a comprehensive clinical assessment, including a careful review of comorbid psychiatric disorders and response to treatments for previous episodes of the disorder. Although most patients with bulimia nervosa are offered a trial of psychotherapy, significant results of controlled trials have contributed to an increased role for medications in the treatment of patients with this disorder. Pharmacologic treatment of anorexia nervosa has similarities to that of treatment-resistant depression, with the clinician turning to open trials and clinical reports for clues to rational management. As described in this article, considerations of potential side effects and medical complications are likely to play an important role in guiding the choice of medication used for treatment of patients with eating disorders.
对神经性贪食症和神经性厌食症患者进行有效的药物治疗规划，是基于全面的临床评估，包括仔细审查共病的精神障碍以及对该疾病既往发作治疗的反应。虽然大多数神经性贪食症患者会接受心理治疗试验，但对照试验的显著结果促使药物在该疾病患者治疗中的作用有所增加。神经性厌食症的药物治疗与难治性抑郁症的治疗有相似之处，临床医生会参考开放试验和临床报告来寻找合理治疗的线索。如本文所述，潜在副作用和医学并发症的考量可能在指导用于治疗饮食失调患者的药物选择方面发挥重要作用。
